Jonas Abrahamsson
YOU?
Author Swipe
View article: Infectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia—A Comparison Between the ALLTogether and NOPHO ALL‐2008 Protocols
Infectious Complications During Early Treatment of Childhood Acute Lymphoblastic Leukemia—A Comparison Between the ALLTogether and NOPHO ALL‐2008 Protocols Open
Introduction Infection remains the most common treatment‐related toxicity of childhood ALL, emphasizing the need to identify patients at risk and to tailor treatment strategies accordingly. Aims The primary aim was to compare infectious to…
View article: The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia
The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia Open
To study the mechanisms of relapse in KMT2A -rearranged ( KMT2A -r) acute lymphoblastic (ALL) and acute myeloid leukemia (AML), we performed whole-genome and exome sequencing of infants and children with relapsed ALL/AML ( n = 36), and lon…
View article: Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study Open
Children with relapsed acute leukemia have a poor prognosis; current relapse treatments are toxic, and novel treatments are needed. The anti‐CD38 antibody isatuximab is approved for relapsed‐refractory multiple myeloma in adults. We presen…
View article: Characteristics and prognosis of paediatric normal karyotype acute myeloid leukaemia: A <scp>NOPHO</scp>‐<scp>DBH AML</scp> study
Characteristics and prognosis of paediatric normal karyotype acute myeloid leukaemia: A <span>NOPHO</span>‐<span>DBH AML</span> study Open
Summary Normal karyotype acute myeloid leukaemia (NK‐AML) in children is a heterogeneous subgroup with scarce data on characteristics and prognosis. We investigated NK‐AML in a large paediatric AML cohort from four trials of the Nordic Soc…
View article: Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial
Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial Open
Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL were included, but neithe…
View article: CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia
CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia Open
Current intensive treatment of pediatric T-cell acute lymphoblastic leukemia (T-ALL) has substantial side effects, highlighting a need for novel biomarkers to improve risk stratification. Canonical biomarkers, such as genetics and immunoph…
View article: Central Nervous System Disease and Outcome in Pediatric Acute Myeloid Leukemia: Results from NOPHO-DBH AML2012 Trial
Central Nervous System Disease and Outcome in Pediatric Acute Myeloid Leukemia: Results from NOPHO-DBH AML2012 Trial Open
Background: Central nervous system disease (CNS3) in pediatric acute myeloid leukemia (pAML) is reported in 6% to 29% of cases. However, its impact on event-free survival (EFS) and overall survival (OS) remains uncertain. This study evalua…
View article: Influence of Nucleophosmin ( <i>NPM1</i> ) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration
Influence of Nucleophosmin ( <i>NPM1</i> ) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration Open
PURPOSE Several genomic subsets of NPM1 mutations with varying sequences (type A, B, D, etc) have been identified. Despite molecular heterogeneity, NPM1 mutations cumulatively portend a more favorable outcome, but biology and prognostic im…
View article: Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with <i>RUNX1</i>::<i>RUNX1T1</i>
Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with <i>RUNX1</i>::<i>RUNX1T1</i> Open
In most study protocols for children with acute myeloid leukemia (AML), treatment response is assessed with flow cytometry (FCM) after one and/or two courses of induction treatment, impacting risk stratification. In AML with RUNX1::RUNX1T1…
View article: Measurable Residual Disease Monitoring during Treatment for Pediatric Acute Myeloid Leukemia in First Relapse Predicts Outcome
Measurable Residual Disease Monitoring during Treatment for Pediatric Acute Myeloid Leukemia in First Relapse Predicts Outcome Open
Despite overall survival (OS) rates of approximately 80% in recent collaborative trials, relapse remains the predominant cause of death in childhood acute myeloid leukemia (AML). We present disease characteristics, prognostic factors, and …
View article: Characterization of Pediatric Acute Myeloid Leukemia With t(7;12)(q36;p13)
Characterization of Pediatric Acute Myeloid Leukemia With t(7;12)(q36;p13) Open
Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is a recurrent translocation in AML in infants or very young children and was recently included in the World Health Organization (WHO) Classification of Hematolymphoid Tumors. AML with t(7…
View article: Haemostasis during early treatment of childhood acute lymphoblastic leukaemia with the <scp>ALLTogether</scp> protocol
Haemostasis during early treatment of childhood acute lymphoblastic leukaemia with the <span>ALLTogether</span> protocol Open
Funding Agencies|Ellen Bachrach Memorial Fund; Swedish Childhood Cancer Fund
View article: Early phase clinical trials in pediatric oncology: Swedish pediatric oncologists’ experiences of balancing hope and expectations in life-threatening illnesses
Early phase clinical trials in pediatric oncology: Swedish pediatric oncologists’ experiences of balancing hope and expectations in life-threatening illnesses Open
Aim To study Swedish pediatric oncologists’ practical and emotional experiences of referring, including and/or treating children in early-phase clinical trials. Methods A nationwide study was conducted using a mixed-method approach. Struct…
View article: Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol
Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol Open
Hyperleukocytosis (HL) in pediatric acute myeloid leukemia (AML) is associated with severe complications and inferior outcome. We report results on HL patients included in the NOPHO-DBH AML 2012 study. We recommended immediate start of ful…
View article: Optimized cytogenetic risk-group stratification of <i>KMT2A</i>-rearranged pediatric acute myeloid leukemia
Optimized cytogenetic risk-group stratification of <i>KMT2A</i>-rearranged pediatric acute myeloid leukemia Open
A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Stu…
View article: Effects of allopurinol on 6-mercaptopurine metabolism in unselected patients with pediatric acute lymphoblastic leukemia: a prospective phase II study
Effects of allopurinol on 6-mercaptopurine metabolism in unselected patients with pediatric acute lymphoblastic leukemia: a prospective phase II study Open
Allopurinol can be used in maintenance therapy (MT) for pediatric acute lymphoblastic leukemia (ALL) to mitigate hepatic toxicity in patients with skewed 6- mercaptopurine metabolism. Allopurinol increases the erythrocyte levels of thiogua…
View article: Early Peripheral Blood Blast Clearance As a Prognostic Marker for Early Treatment Response in Pediatric Acute Myeloid Leukemia
Early Peripheral Blood Blast Clearance As a Prognostic Marker for Early Treatment Response in Pediatric Acute Myeloid Leukemia Open
Background and Significance The cure rate of pediatric acute myeloid leukemia (AML) has improved significantly; however, relapses still occur in up to 30% of the total patient population in high-income countries (HICs), and in an even high…
View article: P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS
P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS Open
Topic: 3. Acute myeloid leukemia - Biology & Translational Research Background: Elevated CD38 expression is present in acute pediatric leukemias, making CD38 a potential target for treating children with acute lymphoblastic leukemia (ALL) …
View article: P468: DETECTION AND CHARACTERIZATION OF RESIDUAL LEUKEMIC CELLS IN CHILDHOOD ACUTE MYELOID LEUKEMIA USING TARGETED DEEP SEQUENCING AND SINGLE CELL MULTI-OMICS
P468: DETECTION AND CHARACTERIZATION OF RESIDUAL LEUKEMIC CELLS IN CHILDHOOD ACUTE MYELOID LEUKEMIA USING TARGETED DEEP SEQUENCING AND SINGLE CELL MULTI-OMICS Open
Background: In children with acute myeloid leukemia (AML), treatment intensification based on measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) shows promising results. However, a substantial proportion of p…
View article: Data from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
Data from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy Open
Mutations in the kinase domain of the ALK kinase have emerged recently as important players in the genetics of the childhood tumor neuroblastoma. Here, we report the appearance of a novel ALK mutation in neuroblastoma, correlating with agg…
View article: Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group Open
PURPOSE A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged ( KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value …
View article: Supplementary Figure Legend from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
Supplementary Figure Legend from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy Open
Supplementary Figure Legend from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
View article: Supplementary Figure Legend from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
Supplementary Figure Legend from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy Open
Supplementary Figure Legend from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
View article: Supplementary Figure 1 from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
Supplementary Figure 1 from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy Open
Supplementary Figure 1 from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
View article: Data from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
Data from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy Open
Mutations in the kinase domain of the ALK kinase have emerged recently as important players in the genetics of the childhood tumor neuroblastoma. Here, we report the appearance of a novel ALK mutation in neuroblastoma, correlating with agg…
View article: Supplementary Figure 1 from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
Supplementary Figure 1 from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy Open
Supplementary Figure 1 from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
View article: Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia
Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia Open
Summary A significant proportion of events in paediatric acute myeloid leukaemia (AML) are caused by resistant disease (RD). We investigated clinical and biological characteristics in 66 patients with RD from 1013 children with AML registe…
View article: Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration
Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration Open
Hypodiploidy, defined as modal numbers (MNs) 45 or lower, has not been independently investigated in pediatric acute myeloid leukemia (AML) but is a well-described high-risk factor in pediatric acute lymphoblastic leukemia. We aimed to cha…